Background
Introduction
The Roundabout (Robo) family proteins are highly conserved transmembrane cell adhesion molecules that are expressed predominantly in neuronal tissues and play a role in the development of the nervous system. [1, 2] Roundabout 4 (Robo4), the fourth member of Robo family, was first identified by Huminiecki et al in 2002 . [3] It is distinct from the other family members in that it is expressed specifically in endothelial cells [4, 5] and hematopoietic stem/progenitor cells (HSPCs). [6, 7] Robo4 acts as a receptor for Slit 2 and modulates vascular endothelial growth factor A (VEGF)-VEGF receptor signaling. [8, 9] The Slit-Robo signaling is essential for angiogenesis, [6, 10] especially tumor angiogenesis. [11] obo4 expression was found to be significantly up-regulated in tumor endothelia compared to their normal counterparts. [12] In addition to angiogenesis, Slit2-Robo4 signaling pathway also plays an essential role in BM homing and mobilization of HSPCs. [7, 13] Smith-Berdan et al demonstrated that Robo4, in cooperation with CXCR4, acted as an HSPC-specific adhesion receptor to localize HSPC to BM niches. [7] Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy regarding the pathogenesis, clinical features and treatment outcomes. In addition to intrinsic changes of leukemic cells including cytogenetic, genetic and epigenetic alterations, impaired hematopoietic microenvironment of the bone marrow (BM) may also contribute to the development of AML. [14] It has been shown that adhesion of AML cells to the BM stromal cells promotes their survival and proliferation. [15, 16] Angiogenesis also plays an important role in AML. [17, 18] Higher BM angiogenesis predicts a higher relapse rate and poorer prognosis in AML patients. [18, 19] Robo4 has been shown to be expressed on leukemic stem cells. [20] However, little is known about the expression of Robo4 and its clinical implications in AML. In the present study, we investigated the BM Robo4 expression by quantitative real-time polymerase chain reaction (RQ-PCR) in a cohort of 218 adults with de novo AML and correlated the results with clinical features, major molecular mutations and outcomes of the patients. To the best of our knowledge, this is the first report to address the prognostic implication of Robo4 expression in AML patients. We found that higher BM Robo4 expression was an independent unfavorable prognostic factor for overall survival (OS) in these patients, and the finding was also validated in an independent validation cohort. sample was tested at least twice independently. The amount of the target gene was normalized to that of the housekeeping gene RPLP0. [17, 24, 25] The copies of target gene were quantified only after successful amplification of the internal control, using the standard curves derived from cloned plasmids. All data were presented as log ratio of the target gene/RPLP0.
Materials and Methods

Patients
Immunohistochemical staining (IHC) for Robo4 protein
We performed IHC to assess the Robo4 protein expression in the BM biopsy specimens from 30 selected AML patients in the original cohort, 17 having higher Robo4 mRNA expression and another 13, lower Robo4 mRNA expression. The tissue section was prepared from formalin-fixed, paraffin-embedded tissue. After deparaffinization and rehydration as previously described, [23] the slides were boiled in 0.01 mol/L citrate buffer (pH = 6.1) for 5 minutes to retrieve the antigens. The endogenous peroxidase activity was blocked by incubation with 3% H 2 O 2 in methanol for 30 minutes. Then the sections were blocked with 10% normal goat serum (VECTASTAIN Elite ABC kit; Vector Laboratories). The primary antibody we used was rabbit polyclonal antihuman Robo4 (PAB12049, Abnova) at a 1:250 dilution. A negative, no-antibody control was included for each staining. The slides were incubated with a biotinylated secondary antibody (1:200 dilution; goat anti-rabbit IgG; VECTASTAIN Elite ABC kit; Vector Laboratories) for 60 minutes at room temperature and AB reagent was applied based on the manufacturer's instructions (VECTASTAIN Elite ABC kit; Vector Laboratories). The antigen detection was conducted by a color reaction with 3,3'-diaminobenzidine (DAB peroxidase substrate kit; catalog number SK-4100; Vector Laboratories). Finally, the sections were counterstained with hematoxylin and mounted. Robo4 expression was assessed by staining intensity and frequency of positively stained cells. A score of 1-5 was calculated for each specimen according to the addition of the score of staining intensity (0 = none, 1 = weak, 2 = strong) and the score of percentage of myeloid cells positively stained (1 = 0~10%, 2 = 10~50%, 3>50%) by the pathologists who were blind to the results of Robo4 mRNA expression. [26] [27] [28] Erythroid cells were excluded from calculation.
Cytogenetics
BM mononuclear cells were harvested directly or after 1-3 day of unstimulated culture as described previously. [29] Metaphase chromosomes were banded by trypsin-Giemsa technique and karyotyped according to the International System for Human Cytogenetic Nomenclature.
Immunophenotype analysis
A panel of monoclonal antibodies to myeloid associated antigens, including CD13, CD33, CD11b, CD15, CD14, and CD41a, as well as lymphoid-associated antigens, including CD2, CD5, CD7, CD19, CD10, and CD20, and lineage nonspecific antigens HLA-DR, CD34, and CD56 were used to characterize the immunophenotypes of the leukemia cells as previously described. [21] Mutation analysis 
Statistical analysis
Cut-off value of Robo4 expression level was determined by sequential cutting strategy and was validated by bootstrap resampling method. The discrete variables of patients with lower and higher Robo4 expression were compared using the Chi-square tests or Fisher's exact test. We used Mann-Whitney U-test to compare continuous variables and medians of distributions. Whole patient population was included for analyses of the correlation between Robo4 expression and clinical characteristics, however, only those receiving conventional standard chemotherapy, as mentioned above, were included in analyses of survivals. OS was measured from the date of first diagnosis to death from any cause or the last follow-up, whereas relapse was defined as a reappearance of at least 5% leukemic blasts in a BM aspirate or new extramedullary leukemia in patients with a previously documented CR. Disease-free status indicated that the patient achieved CR and did not relapse by the end of this study, and disease-free survival (DFS) was defined as the time from recruitment to the first of three events: treatment failure, leukemia relapse or death from any cause. To exclude confounding influences of different treatment regimens, patients who received allogeneic HSCT were censored on the day of cell infusion. [21, 22] We adopted Kaplan-Meier estimation to plot survival curves, and used logrank tests to examine the difference between groups. Relative risk (RR) and 95% confidence interval (CI) were estimated by Cox proportional hazards regression models to determine independent risk factors associated with survival in multivariate analyses. Two-sided P-values less than 0.05 were considered statistically significant. All statistical analyses were accomplished with the SPSS 17 (SPSS Inc., Chicago, IL, USA) and Statsdirect (Cheshire, England, UK).
Results
Correlation of BM Robo4 expression with clinical features and laboratory data in the original cohort
Robo4 expression was significantly higher in AML patients than in normal BM donors.
(P = 0.0007, S1 Fig.) The patients were then divided into two groups: one with lower expression of Robo4 (n = 119) and the other with higher expression (n = 99), by using a cut-off point of 0.010 (Robo4/RPLP0). The comparison of clinical characteristics between patients with lower and higher BM Robo4 expression is shown in Table 1 . Patients with higher BM Robo4 expression had lower white blood cell (WBC) and blast counts than those with lower expression. There was no difference in sex, age and initial hemoglobin levels, platelet counts and serum lactate dehydrogenase levels between the two groups of patients. Compared to patients with lower BM Robo4 expression, those with higher expression had less frequently FAB M3 subtype (P = 0.006, Table 1 ). Higher BM Robo4 expression were positively associated with the expression of HLA-DR (P<0.0001), CD13 (P = 0.0417), CD34 (P = 0.0009) and CD56 (P = 0.039) on the leukemia cells (S1 Table) . There was no difference in the expression of other antigens between the patients with higher and lower Robo4 expression.
Correlation between Robo4 RNA expression and protein expression in the original cohort Correlation of BM Robo4 expression with karyotypes and molecular gene mutations in the original cohort Chromosome data were available in 207 (95%) patients at diagnosis. The comparison of cytogenetic changes between patients with higher and lower BM Robo4 expression is shown in S2 Table. Higher Robo4 expression was closely associated with chromosomal abnormality t (8;21), but inversely correlated with t(15;17) (15.8% versus 1.8%, P = 0.0002 and 1.1% versus 12.5%, P = 0.0019, respectively). With regard to the AML associated genetic alterations (Table 2 ), higher BM Robo4 expression was closely associated with ASXL1 mutation (15.2% versus 6.7%, P = 0.0489) but negatively associated with CEBPA mutation (6.1% versus 18.5%, P = 0.0076). AML patients with higher Robo4 expression had a trend of higher probability of concurrent DNMT3A mutation and KIT mutation (P = 0.0707 and 0.0825, respectively).
Impact of BM Robo4 expression on clinical outcome in the original cohort
Of the 148 AML patients receiving conventional intensive induction chemotherapy, 107 (72.3%) patients achieved a CR ( Table 1 ). The patients with higher Robo4 expression had a trend of a lower CR rate than those with lower Robo4 expression, albeit the difference was not Table) . With a median follow-up of 37.2 months (ranges, 1.0-160), patients with higher Robo4 expression had significantly poorer OS ( Fig. 1) and DFS ( Fig. 2) than those with lower Robo4 expression (median, 17.0 months versus 95.0 months, P = 0.023, and medium, 5.0 months versus 15.0 months, P = 0.024, respectively). In the subgroup of patients with intermediate-risk cytogenetics, the differences between the two groups in OS (S3 Fig.) (median, 13.5 months versus 95.0 months, P = 0.007) and DFS (S4 Fig.) (median, 4.0 months versus 10.0 months, P = 0.025) were even bigger. In multivariate analysis (Table 3) , the independent poor risk factors for OS were older age > 50 years, higher WBC count >50,000/μL, unfavorable karyotype, and higher Robo4 expression (RR 1.779, 95% CI 1.005-3.149, P = 0.048). On the other hand, CEBPA double-mutation and NPM1
+ /FLT3-ITD -(mutant NPM1 in the absence of FLT3-ITD) were independent favorable prognostic factors. The independent poor risk factors for DFS included older age > 50 years, higher WBC count >50,000/μL, unfavorable karyotype, and higher Robo4 expression (RR 1.600, 95% CI 1.026-2.495, P = 0.038). CEBPA double-mutation and NPM1 + /FLT3-ITD -were independent favourable factors for DFS.
The prognostic impact of BM Robo4 expression in the validation cohort
The cut-off point in the original cohort was used to define lower-and higher-expression groups in the validation cohort (n = 53). After a median follow-up time of 39.2 months (range 0.7 to 51.3), higher BM Robo4 expression remained to be a significant unfavorable prognostic factor for OS in total patients (Fig. 3) and those with intermediate-risk cytogenetics in the validation cohort (Fig. 4) (median 13.4 months versus not reached, P = 0.014; median 14.2 months versus not reached, P = 0.017, respectively).
Discussion
Robo4, a receptor for Slit2, is highly expressed in solid tumors, including brain, lung, urinary bladder and colorectal cancers and its expression is restricted to tumor vasculature but downregulated in mature vasculature. [3, 43, 44] Interestingly, up-regulation of Robo4 was noticed in cancerous tissues but not in corresponding noncancerous part using paired samples in 50 patients with colorectal cancers. [43] Robo4 is thus an excellent tumor endothelial markers and a potential target for anti-angiogenesis therapy. [11, 45] There have been few studies concerning the clinical relevance of Robo4 expression in cancers. Gorn et al demonstrated that elevated serum levels of Robo4 before treatment predicted poor prognosis in patients with non-small cell lung cancer, but it did not reach statistical significance in a univariate Cox regression model. [44] To the best of our knowledge, the current study was the first to evaluate Robo4 expression and its clinical implications in AML patients. We demonstrated that Robo4 expression was significantly elevated in AML patients compared to normal controls. Furthermore, higher BM Robo4 expression predicted poorer DFS and OS in AML patients, especially those with intermediate-risk cytogenetics. The prognostic impact of higher BM Robo4 expression was further validated in an independent validation cohort. Robo4, in cooperation with CXCR4, plays a role in BM homing and mobilization of HSPCs. [7, 13] It acts as an HSPC-specific adhesion receptor to localize HSPC to BM niches and its expression is dramatically down-regulated in mobilized HSPCs. [7] It has been shown that mobilization of AML cells by CXCR4 antagonist could enhance chemosensitivity of AML, which is translated into significant survival advantage. [46] Compatible with this finding, AML patients with lower Robo4 expression in the present study were more sensitive to induction chemotherapy and had a trend of higher CR rates.
In the comprehensive analyses of the 17 genetic alterations and cytogenetic changes in the original cohort, we found that higher BM Robo4 expression was closely associated with ASXL1 mutation and t(8;21), but negatively associated with CEBPA mutation and t (15;17) . The translocation t(8;21) is a frequent cytogenetic abnormality in AML; however, the presence of the resultant RUNX1-RUNXT1 fusion protein alone is not sufficient per se to induce leukemia. [47] In the present study, 15 of the 17 patients with t(8;21) showed higher Robo4 expression (S2 Table) . The higher Robo4 expression, which may lead to dysregulation of angiogenesis or microenvironment, may be another hit in patients with this chromosomal abnormality. The significance of close association of higher Robo4 expression and ASXL1 mutation in the pathogenesis of AML needs further exploration.
Conclusions
In conclusion, the present study provides evidences that higher BM Robo4 expression is closely associated with distinct clinical and biologic characteristics in AML patients. Further, higher BM Robo4 expression is an independent poor prognostic factor for OS. The unfavorable prognostic impact of higher BM Robo4 expression was also validated in an independent validation cohort. Higher BM Robo4 expression may serve as a new biomarker for foreseeing the clinical 
